Skip links

Optimize Your Nonclinical & Early Stage Clinical

Camargo Research Group provides managed CRO solutions to streamline and advance drug development programs for emerging biopharma companies.

Success starts with the right partners

For even the most experienced drug development teams, choosing the right strategic partners can be a challenge. Program success is at stake, and you need partners you can trust to validate the safety and efficacy of your molecule. A collaborative, proactive approach is key to manage risk and keep your timeline on track.

As you evaluate potential partners, you find yourself asking:

- Will this partner help execute the right studies? At the right time? For the right price?
- What are the risks and how will I know if our study is on track?
- Who will oversee our studies and how often should I be on site to monitor progress?


Our Solution

Serving as an integrated extension of your team, Camargo Research Group delivers a better way to optimize your outsourcing:

Smart Study Design

Partner with multi-disciplinary experts to optimize study designs and ensure your drug development plan minimizes risk and cost.

Tailored CRO Selection

Find reliable CROs through our network of trusted partners to support your late discovery through early clinical study needs.

Comprehensive Management

Stay on track with program oversight including on-site monitoring and study reporting conducted with your best interest in mind.

InSymbiosis is now part of Camargo

On June 12, 2019, InSymbiosis was acquired by Camargo. The solutions now available through Camargo Research Group are the same as those previously offered through InSymbiosis.

In addition to the nonclinical development support you have come to know through InSymbiosis, together as Camargo, we deliver more. Our portfolio accelerates your path to market through integrated solutions including Development and Regulatory Strategy, CMC, and Clinical & PK. Explore our comprehensive solutions over on the Camargo website.

For more information about the acquisition, read our press release.

The Canadian Advantage

In today's global drug development landscape, there are many study site options. Why are we based in Montreal? Canada offers world-class CROs, leading principal investigators and globally competitive pricing. Our close proximity to these resources enables us to deliver high-touch study execution services at a favorable cost.